Allogene Therapeutics presents investigational pipeline and corporate strategy at London conference

Allogene Therapeutics presents investigational pipeline and corporate strategy at London conference
Allogene pipeline and strategy update

Allogene Therapeutics announced that CEO Zachary Roberts, MD, PhD, provided an update on the company’s investigational drug pipeline and corporate strategy at the UBS Global Biopharma Conference in London.

The presentation is available for replay through the Investors section of the company’s website. Allogene is actively developing therapies in the cell therapy sector, aiming to advance treatments for cancer and other conditions.

Earlier this year, Allogene Therapeutics unveiled an interim futility analysis for its ALPHA3 program and detailed an expansion of its allogeneic CART portfolio at SITC2026. The company has remained focused on advancing experimental cell therapies. Its pipeline development remains a key area of interest for stakeholders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.